Truist Financial’s Impax Laboratories, Inc. IPXL Stock Holding History

Truist Financial’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-8,433	Closed	-$253K	–	805
2014 Q2	$253K	Sell	8,433 -717	-8%	-$19.3K	0.01%	688
2014 Q1	$241K	Sell	9,150 -770	-8%	-$19.2K	0.01%	704
2013 Q4	$250K	Sell	9,920 -560	-5%	-$12.5K	0.01%	687
2013 Q3	$214K	Buy	+10,480	New	+$216K	0.01%	692

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Truist Financial's IPXL Position: Q3 2014 in Review

Truist Financial sold out of Impax Laboratories, Inc. (IPXL) in Q3 2014, closing a stake of 8,433 shares — an estimated $253K sold.

Truist Financial first reported a position in IPXL in Q3 2013 and held it in 4 quarters. The position peaked at $253K in Q2 2014. 162 funds tracked by Wall St. Rank hold IPXL as of Q3 2014.

Truist Financial reported no remaining Impax Laboratories, Inc. position as of Q3 2014 after selling out during the quarter.
Truist Financial sold 8,433 Impax Laboratories, Inc. shares in Q3 2014, an estimated $253K.
Truist Financial first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 4 quarters.
Truist Financial's Impax Laboratories, Inc. position peaked at $253K in Q2 2014.
162 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2014.

Based on Truist Financial's 13F filing for Q3 2014, filed 21 Oct 2014.